High DYRK1A expression was observed in tumour samples from patients with lung cancer compared with that in normal lung tissues, as shown in Figure 1A (Overexpression gene rank: 177).19 Furthermore, we also observed that a high level of DYRK1A was correlated with a reduced survival time in patients with lung cancer using a Kaplan‐Meier plotter analysis (Figure 1B, P = 1.5e‐6).20 Thus, we hypothesized that DYRK1A might play a critical role in NSCLC progression and that targeting DYRK1A might be an efficient therapeutic strategy to treat patients with NSCLC. This evidence concerns the gene DYRK1A and lung carcinoma.